Hepatitis C, Chronic: all 1,090 studies
Page 5 of 11. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.CompletedNCT00087633Phase 4Results posted
- Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).CompletedNCT00087607Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.CompletedNCT00087594Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + RibavirinCompletedNCT00087568Phase 4Results posted
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)CompletedNCT00081770Phase 3Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).CompletedNCT00077649Phase 4Results posted
- ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.CompletedNCT00077636Phase 4Results posted
- Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3CompletedNCT00056862Phase 4Results posted
- Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)CompletedNCT00049842Phase 3Results posted
- Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)CompletedNCT00048724Phase 3Results posted
- PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)CompletedNCT00039871Phase 3Results posted
- Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney DiseaseCompletedNCT00028093Phase 4Results posted
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard TreatmentCompletedNCT00006164Phase 3Results posted
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVActive, not recruitingNCT07037277Phase 3
- Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis CTerminatedNCT06564051
- Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver ClinicsActive, not recruitingNCT05895448Phase 4
- Eliminating HCV Infection Among PWUDStatus unknownNCT05474781
- Evaluating the Chain of Addiction Care (CAC)Status unknownNCT05401136
- Possible Differences in HCC Course Depending on DAA TreatmentStatus unknownNCT05376943
- Long Term Follow up of Chronic HCV Patients Receiving DAASStatus unknownNCT05170490
- Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During PregnancyActive, not recruitingNCT05140941Phase 4
- Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)CompletedNCT05138523
- Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve ChildrenCompletedNCT05091008Phase 2
- Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action AntiviralsCompletedNCT05062408
- The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in ChinaStatus unknownNCT04997564Phase 4
- Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis CStatus unknownNCT04952207
- Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral DrugsCompletedNCT04943588
- 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis CCompletedNCT04885855Phase 2/3
- The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionCompletedNCT04774107Phase 1
- Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-respondersCompletedNCT04695769Phase 4
- Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis AccessWithdrawnNCT04614142Phase 4
- HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in BrusselsCompletedNCT04610762
- Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological ResponseCompletedNCT04577482
- Prediction of Liver-related Outcomes After HCV CureStatus unknownNCT04460157
- Screening for Chronic Hepatitis C Virus in Hospitalized PatientsCompletedNCT04437277Not applicable
- A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe ProgramsStatus unknownNCT04428346Not applicable
- Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 PatientsCompletedNCT04391985Phase 1/2
- ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced ParticipantsCompletedNCT04387539Phase 1/2
- Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4CompletedNCT04387526Phase 2/3
- Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian PatientsCompletedNCT04385407Phase 2
- Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 InfectionCompletedNCT04382937Phase 3
- Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver CirrhosisCompletedNCT04352309
- Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical TrialCompletedNCT04330508
- Therapeutic Hepatitis C Virus VaccineStatus unknownNCT04318379Phase 1
- Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected SubjectsWithdrawnNCT04309734Phase 1/2
- Rapid HCV RNA Testing and LInkage to CareTerminatedNCT04302948Not applicable
- An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis CStatus unknownNCT04301882
- Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1CompletedNCT04246723Phase 2
- Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy SubjectsCompletedNCT04232514Phase 1
- Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis CStatus unknownNCT04220151
- A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C VirusCompletedNCT04214028
- Metabolic Changes in Chronic HCV Patients Receiving DAASStatus unknownNCT04211844
- Hepatitis C Elimination in the NetherlandsStatus unknownNCT04208035
- The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected SubjectsCompletedNCT04202952Phase 1/2
- Voices From the Black Community: Hepatitis C Research ParticipationCompletedNCT04202081
- The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected SubjectsCompletedNCT04201275Phase 1
- A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian FederationCompletedNCT04189627
- Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 VillagesCompletedNCT04177043Phase 4
- Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina FasoStatus unknownNCT04136405
- Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus InfectionCompletedNCT04094272
- Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis CStatus unknownNCT04071353
- SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis CStatus unknownNCT04070235Phase 2/3
- Eliminate Hepatitis C/EC Partnership Evaluation ProtocolStatus unknownNCT04061551Not applicable
- Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in BrazilStatus unknownNCT04039698Not applicable
- Re-engaging Patients With Hepatitis C Into CareStatus unknownNCT04029246Not applicable
- Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) InfectionCompletedNCT04019717Phase 2
- Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe ProgramsCompletedNCT04014179Not applicable
- KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis CCompletedNCT03995485Phase 3
- Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong KongActive, not recruitingNCT03993925
- Glecaprevir/Pibrentasvir Real-world Study in ChinaStatus unknownNCT03941821
- Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological MalignancyCompletedNCT03903185Phase 1/2
- The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult SubjectsCompletedNCT03903081Phase 1
- Evaluation of Dried Blood Spot for HCV RNA TestingCompletedNCT03896087Not applicable
- Effect of Strategies for the Treatment of Chronic Hepatitis C in ColombiaStatus unknownNCT03895294Not applicable
- Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral AgentsStatus unknownNCT03894696
- Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)Status unknownNCT03888729Phase 4
- Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)Status unknownNCT03887637
- Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients SeraStatus unknownNCT03882307Early Phase 1
- Direct Acting Antivirals for HCV Infection in Kidney Transplant RecipientsCompletedNCT03880682
- Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian FederationCompletedNCT03868163
- Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)CompletedNCT03833362Phase 3
- The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult SubjectsCompletedNCT03811678Phase 1
- ATTIC - Access To Treat in the CommunityTerminatedNCT03797066Phase 4
- Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in JiangsuStatus unknownNCT03772002Not applicable
- Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 YearsCompletedNCT03764345Not applicable
- Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison SettingCompletedNCT03740906
- An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New DrugsCompletedNCT03740230
- Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney TransplantationTerminatedNCT03723824Phase 4
- Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.Status unknownNCT03721627Phase 4
- A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND StudyCompletedNCT03710252Phase 4
- Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for VasculitisCompletedNCT03693586
- The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV PatientsStatus unknownNCT03687229
- The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult SubjectsCompletedNCT03673696Phase 1
- Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral TherapyCompletedNCT03612973Not applicable
- Evaluation of HCV Viremia Testing Approaches Among PWID in GeorgiaCompletedNCT03594838Not applicable
- Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4CompletedNCT03578640Phase 3
- Transmission of Chronic Hepatitis C in PregnancyCompletedNCT03570112
- Epidemiology of Chronic Hepatitis C and Disease ModellingCompletedNCT03566563
- Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 TrialStatus unknownNCT03551444Phase 3
- Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San DiegoStatus unknownNCT03551002